About · The publisher and the method
A capsule file for the GHK-Cu copper-peptide literature
What this file is, what it is not, and how each capsule of evidence gets sourced before it is filed.
What this site is
Telehealth GHK-Cu is a capsule file for the peer-reviewed research on GHK-Cu, the copper-binding tripeptide also known as Copper Tripeptide-1. The organizing idea is borrowed from the molecule's own consumer life: this literature is unusually chunkable into discrete, labelled findings — a hair-count delta, a procollagen comparison, a peak-collagen concentration, a gene-modulation percentage, a copper stability constant — so each is rendered as a clean capsule, hair-follicle research leading, with collagen, gene-expression, and wound-repair work behind it.
What the file is not is a place that acts on any of that. It diagnoses no one, prescribes nothing, and treats nothing; it keeps no clinical staff, connects no one to a prescriber, and has nothing on a shelf to sell. It stands beside the literature and reads it — a publisher next to the record, not a provider between a reader and a treatment.
What 'telehealth' means here — and what it does not
The word 'telehealth' in the name describes a register, not a service. It is the voice a well-built wellness explainer uses to walk through a concept — accessible, modern — and nothing more: no appointment, no consultation, no prescription pad, no checkout. No telehealth visit is offered here, no one is connected to a prescriber, and nothing on these pages is for sale.
The distinction is stated plainly because it is easy to blur. A reader landing on a copper-peptide page deserves to know at once whether they are reading marketing, a medical service, or a careful reading of the science. It is the third.
How we handle the evidence
Every quantitative claim in the file — every dose, percentage, n-value, half-life, and effect size — carries a numbered citation from the published record, listed in full on the references page. Each entry describes what was administered to which species at which concentration by which route; none of it is translated into a human dosing recommendation, because GHK-Cu's systemic use is unapproved and has no validated human pharmacokinetic basis [6].
The shape of the evidence is stated honestly, too. The strongest data are topical and dermatologic [3]. The hair-regrowth signal comes from a combination formulation, not pure GHK-Cu [4]. Some follicle-level work uses an analog, AHK-Cu, rather than GHK-Cu itself [8]. And much of the foundational mechanistic literature traces to a single investigator, so independent replication of the broadest claims is still limited. Where the evidence is strong, that is said plainly; where it thins, the gap is tagged rather than papered over.